<DOC>
	<DOCNO>NCT02102490</DOCNO>
	<brief_summary>The main purpose study evaluate whether study drug know abemaciclib effective treating participant breast cancer already try drug treatment .</brief_summary>
	<brief_title>A Study Of Abemaciclib ( LY2835219 ) In Participants With Previously Treated Breast Cancer That Has Spread</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion Criteria . Have diagnosis Hormone Receptor Positive ( HR+ ) , Human Epidermal Growth Factor Receptor 2 Negative ( HER2 ) breast cancer . Recurrent , locally advanced , unresectable metastatic breast cancer disease progression follow antiestrogen therapy . Prior treatment least 2 chemotherapy regimen : At least 1 regimen must administer metastatic setting . At least 1 regimen must contain taxane . No 2 prior chemotherapy regimen metastatic setting . Have performance status ( PS ) 0 1 Eastern Cooperative Oncology Group scale . Have discontinue previous therapy cancer . Have presence measureable disease define Response Evaluation Criteria Solid Tumors Version 1.1 . Have either history central nervous system ( CNS ) metastasis evidence CNS metastasis magnetic resonance image brain obtain baseline . Received prior therapy another CDK4/6 inhibitor . Have receive treatment drug receive regulatory approval indication within 14 21 day initial dose study drug . Have major surgery within 14 day initial dose study drug . Have history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Endocrine Therapy , Taxane , MONARCH 1</keyword>
</DOC>